Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Dusheiko

Showing results (21-30 of 115) with videos related to

Pageof 12
Sort By:
The Lancet. Infectious Diseases|March 17, 2015
Hope for non-responders with hepatitis C virus and cirrhosisGeoffrey Dusheiko, Douglas MacDonald
Gastroenterology|January 15, 2019
Hepatitis B Surface Antigen Loss: Too Little, Too Late and the Challenge for the FutureGeoffrey Dusheiko, Bo Wang
Lancet (London, England)|March 19, 2013
Hepatitis C treatment: interferon free or interferon freer?Geoffrey Dusheiko, Tabinda Burney
The Lancet. Global Health|August 1, 2019
Antiviral treatment for hepatitis C: rebalancing cost, affordability, and availabilityGeoffrey Dusheiko, Charles Gore
Gut|September 1, 2012
New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbyeGeoffrey Dusheiko, Heiner Wedemeyer
Nature Clinical Practice. Gastroenterology & Hepatology|November 3, 2005
Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?Geoffrey Dusheiko, Mark Danta
Drugs of Today (Barcelona, Spain : 1998)|August 29, 2007
Telbivudine for the treatment of chronic hepatitis BGeoffrey Dusheiko, Mark Danta
Expert Review of Anti-Infective Therapy|December 15, 2010
Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patientsTabinda Burney, Geoffrey Dusheiko
The Lancet. Gastroenterology & Hepatology|November 9, 2024
The surety or otherwise of leaving chronic hepatitis B untreatedGeoffrey Dusheiko, Mzamo Mbelle
Journal of Hepatology|May 20, 2019
An appraisal of the WHO hepatitis B treatment guidelines applicability to AfricansGeoffrey Dusheiko, Maud Lemoine
Pageof 12

Showing results (21-30 of 115) with videos related to

Sort By:
Pageof 12
The Lancet. Infectious Diseases|March 17, 2015
Hope for non-responders with hepatitis C virus and cirrhosisGeoffrey Dusheiko, Douglas MacDonald
Gastroenterology|January 15, 2019
Hepatitis B Surface Antigen Loss: Too Little, Too Late and the Challenge for the FutureGeoffrey Dusheiko, Bo Wang
Lancet (London, England)|March 19, 2013
Hepatitis C treatment: interferon free or interferon freer?Geoffrey Dusheiko, Tabinda Burney
The Lancet. Global Health|August 1, 2019
Antiviral treatment for hepatitis C: rebalancing cost, affordability, and availabilityGeoffrey Dusheiko, Charles Gore
Gut|September 1, 2012
New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbyeGeoffrey Dusheiko, Heiner Wedemeyer
Nature Clinical Practice. Gastroenterology & Hepatology|November 3, 2005
Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?Geoffrey Dusheiko, Mark Danta
Drugs of Today (Barcelona, Spain : 1998)|August 29, 2007
Telbivudine for the treatment of chronic hepatitis BGeoffrey Dusheiko, Mark Danta
Expert Review of Anti-Infective Therapy|December 15, 2010
Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patientsTabinda Burney, Geoffrey Dusheiko
The Lancet. Gastroenterology & Hepatology|November 9, 2024
The surety or otherwise of leaving chronic hepatitis B untreatedGeoffrey Dusheiko, Mzamo Mbelle
Journal of Hepatology|May 20, 2019
An appraisal of the WHO hepatitis B treatment guidelines applicability to AfricansGeoffrey Dusheiko, Maud Lemoine
Pageof 12